NCT04959812View on ClinicalTrials.gov

Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Sufentanil

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

September 8, 2023

Study Completion Date

September 8, 2023

Conditions
Healthy
Interventions
DRUG

Sufentanil

Subjects will receive Sufentanil while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.

OTHER

Placebo

Subjects will receive a placebo pill while the effects of this placebo on tolerance to a hemorrhagic insult will be assessed.

Trial Locations (2)

75231

Institute for Exercise and Environmental Medicine, Dallas

75390

University of Texas Southwestern Medical Center, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER